stockrow
Friday 6 November 2026
Export IMRN’s income statement to Excel — free account
IMMURON
IMRN Healthcare Biotechnology
IMMURON’s revenue for fiscal 2026 (year ended June 2026) was $5.2 million, up 10.9% from fiscal 2025.
0.82
0.03
−3.53%
Follow IMRN
Alert me
Target Price Range
Analyst price targets
Free accountTen years at a glance Fiscal years to June
| Ten-year view | Analyst estimates Powerpack | ||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Group | Line | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Trend | 10 yrs | 2027e | 2028e | 2029e | Next 3/yr |
| Income, $m | |||||||||||||||||
| Income, $m | Revenue | 1 | 1 | 2 | 2 | 0 | 1 | 1 | 3 | 5 | 5 | +19.5% | — | — | — | — | |
| Gross margin, % | 75.82 | 77.28 | 72.05 | 72.65 | 65.01 | 68.42 | 72.54 | 68.06 | 65.39 | 64.50 | (11.3) pt | ||||||
| EBT | (5) | (2) | (3) | (2) | (6) | (2) | (3) | (5) | (3) | (2) | (7.7%) | ||||||
| EBT margin, % | (487.34) | (163.38) | (194.04) | (116.23) | (5,752.89) | (373.05) | (209.82) | (141.49) | (71.58) | (47.71) | +439.6 pt | ||||||
| Net income | (5) | 0 | (3) | (2) | (6) | (2) | (3) | (5) | (3) | (2) | (7.7%) | ||||||
| Per share, $ | |||||||||||||||||
| Per share, $ | Revenue | 0.40 | 0.43 | 0.47 | 0.38 | 0.02 | 0.10 | 0.21 | 0.56 | 0.82 | 0.70 | +6.6% | |||||
| Earnings | (1.94) | (0.71) | (0.92) | (0.45) | (1.17) | (0.36) | (0.45) | (0.80) | (0.59) | (0.37) | (16.8%) | ||||||
| Cash flow | (2.00) | (0.82) | (0.36) | (0.48) | (0.55) | (0.40) | (0.31) | (0.68) | (0.69) | (0.30) | (19.1%) | ||||||
| Capex | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | (14.3%) | ||||||
| Free cash flow | (2.00) | (0.82) | (0.36) | (0.48) | (0.55) | (0.40) | (0.31) | (0.68) | (0.69) | (0.30) | (19.1%) | ||||||
| Book value | 1.87 | 1.96 | 1.45 | 0.86 | 3.50 | 2.96 | 2.32 | 1.46 | 0.91 | 1.02 | (6.5%) | ||||||
| Shares, m | 3 | 3 | 4 | 4 | 6 | 6 | 6 | 6 | 6 | 7 | +12.1% | ||||||
| Valuation, × | |||||||||||||||||
| Valuation, × | P/E | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.0 | |||||
| P/S | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.0 | ||||||
| P/B | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.0 | ||||||
| EV/Sales | 0.00 | 0.00 | 0.00 | (0.63) | (10.00) | (24.73) | (7.30) | (4.35) | (1.01) | (3.47) | (5.2) | ||||||
| EV/FCF | 0.00 | 0.00 | 0.54 | 0.45 | 2.27 | 1.77 | 1.99 | 1.00 | 0.15 | 0.58 | 0.9 | ||||||
| Cash, $m | |||||||||||||||||
| Cash, $m | Operating cash flow | (5) | (3) | (1) | (2) | (3) | (2) | (2) | (4) | (4) | (2) | (9.3%) | |||||
| Capex | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | — | 0 | (3.2%) | ||||||
| Free cash flow | (5) | (3) | (1) | (2) | (3) | (2) | (2) | (4) | (4) | (2) | (9.2%) | ||||||
| Balance, $m | |||||||||||||||||
| Balance, $m | Working capital | 5 | 5 | 4 | 3 | 18 | 16 | 12 | 8 | 5 | 8 | +4.9% | |||||
| Net debt | (3) | (4) | (4) | (2) | (19) | (16) | (13) | (8) | (2) | (6) | +8.6% | ||||||
| Shareholders’ equity | 5 | 7 | 5 | 4 | 19 | 17 | 13 | 8 | 5 | 8 | +4.8% | ||||||
| Returns, % | |||||||||||||||||
| Returns, % | ROA | (164.22) | (34.81) | (49.86) | (38.21) | (51.40) | (10.83) | (15.53) | (36.39) | (40.31) | (32.26) | +132.0 pt | |||||
| ROIC | (153.23) | (47.94) | (129.77) | (76.44) | (618.08) | (168.08) | (357.94) | (547.06) | (80.60) | (146.14) | +7.1 pt | ||||||
| ROE | (118.87) | (40.60) | (56.16) | (43.45) | (54.15) | (11.45) | (16.98) | (42.24) | (49.82) | (39.02) | +79.9 pt | ||||||
| People | |||||||||||||||||
| People | Employees | 7 | 5 | 6 | 5 | 4 | 5 | 6 | 7 | 7 | 7 | 0.0% | |||||
| Revenue/emp, $m | 0.15 | 0.29 | 0.28 | 0.34 | 0.03 | 0.11 | 0.20 | 0.46 | 0.67 | 0.75 | +19.5% | ||||||
Negative figures in brackets.
estimates
Fiscal years to Jun 2026 · fundamentals updated 2 Nov 2026
IMMURON vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| VTGN VistaGen Therapeutics, Inc. | $7.3M | — (loss-making) | — (loss-making) | +504.92% (above 0%: growing) | n/m | +22.23% (above 0%: growing) | 100.00% | (904.34%) | Compare |
| SNGX Soligenix Inc. | $7.3M | — (loss-making) | — (loss-making) | −98.89% (below 0%: shrinking) | n/m | +37.83% (above 0%: growing) | 0.00% | 0.00% | Compare |
| XTLB XTL Biopharmaceuticals Ltd. | $7.3M | — (loss-making) | — | −39.32% (below 0%: shrinking) | 0.00% | +46.78% (above 0%: growing) | 0.00% | 0.00% | Compare |
| MTVA MetaVia Inc. | $7.2M | — (loss-making) | — | — | n/m | −22.42% (below 0%: shrinking) | — | 0.00% | Compare |
| ENSC Ensysce Biosciences, Inc. | $7.0M | — (loss-making) | — (loss-making) | −15.10% (below 0%: shrinking) | n/m | +27.50% (above 0%: growing) | 100.00% | (221.28%) | Compare |
| BCLI Brainstorm Cell Therapeutics Inc. | $7.0M | — (loss-making) | — | — | n/m | +74.44% (above 0%: growing) | 0.00% | 0.00% | Compare |
| IMRN IMMURON | $6.9M | — (loss-making) | — | +757.00% (above 0%: growing) | +12.00% (above 0%: growing) | +42.55% (above 0%: growing) | 72.16% | 0.00% | |
| SYBX Synlogic, Inc. | $6.7M | — (loss-making) | — (loss-making) | −95.40% (below 0%: shrinking) | n/m | −277.87% (below 0%: shrinking) | 100.00% | 0.00% | Compare |
| KPRX Kiora Pharmaceuticals, Inc. | $6.6M | — (loss-making) | — (loss-making) | −93.64% (below 0%: shrinking) | n/m | +50.06% (above 0%: growing) | 100.00% | 0.00% | Compare |
| Median of peers | $7.1M | — | — | −66.48% | — | +32.67% | 100.00% | 0.00% |